Skip to main content

Table 1 Baseline characteristics

From: Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

  Implementation group (n = 119) Control group (n = 93) Total (n = 212)
Sex (male)—n (%) 63 (52.94) 51 (54.84) 114 (53.77)
Age (years)
 mean 72.14 69.65 71.21
 SD 10.67 14.23 12.20
Amiodarone—n (%) 3 (2.52) 4 (4.26) 7(3.30)
Alcohol intake (units per day)—n (%)
 < 1 62 (52.99) 62(66.67) 122(58.10)
 1–5 34(29.06) 21(22.34) 57(27.14)
 6–14 10(8.55) 7(7.45) 19(9.05)
 15–21 9(7.69) 1(1.06) 10(4.76)
 22–49 2(1.71) 2(2.13) 4(1.90)
 missing 2   2
Smoking status—n (%)
 Current 19(16.10) 14(14.89) 33(15.64)
 Previous 39(33.05) 37(39.78) 76(36.02)
 Never 60(50.85) 42(44.68) 102(48.34)
 Missing 1   1
Indication—n (%)
 AF 111 (93.28) 56(59.57) 167(78.77)
 DVT 4(3.36) 17(18.09) 21(9.91)
 PE 4(3.36) 20(21.51) 24(11.32)
CYP2C9*2—n (%)
 *1/*1 91 (76.47)   
 *1/*2 27(22.69)   
 *2/*2 1(0.84)   
CYP2C9*3—n (%)    
 *1/*1 105(88.24)   
 *1/*3 14(11.76)   
 *3/*3 0 (0.00)   
VKORC1—n (%)
 G/G 49(41.18)   
 G/A 57(47.90)   
 A/A 13(10.92)   
Target INR range—n (%)
 2–3 115(96.64) 92(98.93) 207(97.64)
 2–2.5 0(0.00) 1(1.06) 1(0.47)
 2.5–3.5 3(2.52) 0(0.00) 3(1.42)
 1.8–3.2 1(0.84) 0(0.00) 1(0.47)